Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection

Douglas Norman, C. F. Shield, John Barry, W. M. Bennett, K. Henell, J. Kimball, B. Funnell, B. Hubert

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

OKT3 monoclonal anti-T cell antibody was used during the first 2 weeks following cadaveric renal transplantation to prevent rejection. When compared with a control group receiving triple immunosuppression with cyclosporine, azathioprine, and prednisone, the OKT3, azathioprine, and prednisone group had significantly fewer acute rejections during the first month (6% v 50%; P <0.01), and the mean time of onset of the first rejection was significantly delayed (day 47 v day 8; P <0.01) in the OKT3 prophylaxis group. OKT3 was administered intraoperatively safely and without complications on the day of transplantation. The well-reported first dose reaction to OKT3 was similar in these patients when compared with patients receiving OKT3 for treatment of rejection. Anti-OKT3 antibody development occurred in half of the patients receiving OKT3, and did not prevent the subsequent use of OKT3 in these patients, whose rejections following OKT3 prophylaxis were steroid reversible. There were no deaths among the patients receiving prophylactic OKT3, and during a 15-month follow-up, only three of 34 kidneys were lost for any reason. In addition to its use for primary and steroid-resistant rejection, OKT3 may be useful early after transplantation to prevent rejection.

Original languageEnglish (US)
Pages (from-to)107-110
Number of pages4
JournalAmerican Journal of Kidney Diseases
Volume11
Issue number2
StatePublished - 1988

Fingerprint

Muromonab-CD3
Kidney Transplantation
Azathioprine
Prednisone
Transplantation
Steroids
Immunosuppression
Cyclosporine
Anti-Idiotypic Antibodies

ASJC Scopus subject areas

  • Nephrology

Cite this

Norman, D., Shield, C. F., Barry, J., Bennett, W. M., Henell, K., Kimball, J., ... Hubert, B. (1988). Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection. American Journal of Kidney Diseases, 11(2), 107-110.

Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection. / Norman, Douglas; Shield, C. F.; Barry, John; Bennett, W. M.; Henell, K.; Kimball, J.; Funnell, B.; Hubert, B.

In: American Journal of Kidney Diseases, Vol. 11, No. 2, 1988, p. 107-110.

Research output: Contribution to journalArticle

Norman, D, Shield, CF, Barry, J, Bennett, WM, Henell, K, Kimball, J, Funnell, B & Hubert, B 1988, 'Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection', American Journal of Kidney Diseases, vol. 11, no. 2, pp. 107-110.
Norman, Douglas ; Shield, C. F. ; Barry, John ; Bennett, W. M. ; Henell, K. ; Kimball, J. ; Funnell, B. ; Hubert, B. / Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection. In: American Journal of Kidney Diseases. 1988 ; Vol. 11, No. 2. pp. 107-110.
@article{3e4fadeabba644a095d9eaafcbe5d32e,
title = "Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection",
abstract = "OKT3 monoclonal anti-T cell antibody was used during the first 2 weeks following cadaveric renal transplantation to prevent rejection. When compared with a control group receiving triple immunosuppression with cyclosporine, azathioprine, and prednisone, the OKT3, azathioprine, and prednisone group had significantly fewer acute rejections during the first month (6{\%} v 50{\%}; P <0.01), and the mean time of onset of the first rejection was significantly delayed (day 47 v day 8; P <0.01) in the OKT3 prophylaxis group. OKT3 was administered intraoperatively safely and without complications on the day of transplantation. The well-reported first dose reaction to OKT3 was similar in these patients when compared with patients receiving OKT3 for treatment of rejection. Anti-OKT3 antibody development occurred in half of the patients receiving OKT3, and did not prevent the subsequent use of OKT3 in these patients, whose rejections following OKT3 prophylaxis were steroid reversible. There were no deaths among the patients receiving prophylactic OKT3, and during a 15-month follow-up, only three of 34 kidneys were lost for any reason. In addition to its use for primary and steroid-resistant rejection, OKT3 may be useful early after transplantation to prevent rejection.",
author = "Douglas Norman and Shield, {C. F.} and John Barry and Bennett, {W. M.} and K. Henell and J. Kimball and B. Funnell and B. Hubert",
year = "1988",
language = "English (US)",
volume = "11",
pages = "107--110",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection

AU - Norman, Douglas

AU - Shield, C. F.

AU - Barry, John

AU - Bennett, W. M.

AU - Henell, K.

AU - Kimball, J.

AU - Funnell, B.

AU - Hubert, B.

PY - 1988

Y1 - 1988

N2 - OKT3 monoclonal anti-T cell antibody was used during the first 2 weeks following cadaveric renal transplantation to prevent rejection. When compared with a control group receiving triple immunosuppression with cyclosporine, azathioprine, and prednisone, the OKT3, azathioprine, and prednisone group had significantly fewer acute rejections during the first month (6% v 50%; P <0.01), and the mean time of onset of the first rejection was significantly delayed (day 47 v day 8; P <0.01) in the OKT3 prophylaxis group. OKT3 was administered intraoperatively safely and without complications on the day of transplantation. The well-reported first dose reaction to OKT3 was similar in these patients when compared with patients receiving OKT3 for treatment of rejection. Anti-OKT3 antibody development occurred in half of the patients receiving OKT3, and did not prevent the subsequent use of OKT3 in these patients, whose rejections following OKT3 prophylaxis were steroid reversible. There were no deaths among the patients receiving prophylactic OKT3, and during a 15-month follow-up, only three of 34 kidneys were lost for any reason. In addition to its use for primary and steroid-resistant rejection, OKT3 may be useful early after transplantation to prevent rejection.

AB - OKT3 monoclonal anti-T cell antibody was used during the first 2 weeks following cadaveric renal transplantation to prevent rejection. When compared with a control group receiving triple immunosuppression with cyclosporine, azathioprine, and prednisone, the OKT3, azathioprine, and prednisone group had significantly fewer acute rejections during the first month (6% v 50%; P <0.01), and the mean time of onset of the first rejection was significantly delayed (day 47 v day 8; P <0.01) in the OKT3 prophylaxis group. OKT3 was administered intraoperatively safely and without complications on the day of transplantation. The well-reported first dose reaction to OKT3 was similar in these patients when compared with patients receiving OKT3 for treatment of rejection. Anti-OKT3 antibody development occurred in half of the patients receiving OKT3, and did not prevent the subsequent use of OKT3 in these patients, whose rejections following OKT3 prophylaxis were steroid reversible. There were no deaths among the patients receiving prophylactic OKT3, and during a 15-month follow-up, only three of 34 kidneys were lost for any reason. In addition to its use for primary and steroid-resistant rejection, OKT3 may be useful early after transplantation to prevent rejection.

UR - http://www.scopus.com/inward/record.url?scp=0023845121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023845121&partnerID=8YFLogxK

M3 - Article

C2 - 3277400

AN - SCOPUS:0023845121

VL - 11

SP - 107

EP - 110

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 2

ER -